The agmdhope’s Podcast

August 2025 Virtual Gastroparesis Awareness Month Program Series Featuring Chris Quesenberry. In this program, Chris discusses Advocating for Gastroparesis – A Pharmaceutical Company’s Journey.

In this program, Chris discusses Advocating for Gastroparesis – A Pharmaceutical Company’s Journey.

In this interview, Dr. Mark Pimentel discusses Irritable Bowel Syndrome. 

AGMD is honored to have Dr. Bolaji Ayinde present Functional Dyspepsia for our Neurogastroenterology and Motility Expert Series.

In this program, Dr. Sharma discusses Clues and Cues from the Neurogastroenterologist: Gastroparesis and Functional Dyspepsia in EDS.
 
Dr. Sharma is currently the Donald O. Castell Endowed Chair in Gastroenterologyat the Medical University of South Carolina (MUSC). He has a clinical andtranslational focus in Neurogastroenterology & Motility (NGM), particularlydiabetic gastroparesis and Parkinson’s disease. He obtained his medical degree atVirginia Commonwealth University, completed internal medicine residency atTemple University Hospitals, and GI fellowship at Penn State Hershey MedicalCenter. After completing training, he spent 10 years on faculty at the MedicalCollege of Georgia. Dr. Sharma’s research focus is understanding thepathophysiology of gut-brain axis in various conditions and developing innovative,non-invasive, and promising neuromodulation therapies through his insights,mentorship and collaborations, and his engineering background. He currentlyserves as principal investigator of a NIH-funded multi-center, randomized, sham-controlled study investigating thoracic neuromodulation for diabetic gastroparesis(RO1-DK133520) and a MPI of a Gastroenterology-Neurology Research Centers ofthe Consortium of Gut-Brain Communication in Parkinson disease (U01-DK140923).

In this program, Chris discusses Advocating for Gastroparesis – A Pharmaceutical Company’s Journey.
Chris is the Chief Commercial Officer at Evoke Pharma, Inc.

AGMD is proud to present our series featuring Dr. Kenneth Koch.  Every other month, we will be having a conversation with Dr. Koch and focusing on various topics related to gastroparesis.
 
This month, Dr. Koch will discuss the Differences Between Diabetic, Idiopathic, and Secondary Causes of Gastroparesis.
 
There will be ample time for questions towards the end of the program.
 
Kenneth L. Koch, MD is Professor of Medicine, Section on Gastroenterology & Hepatology, at Wake Forest Baptist Medical Center. He has a career-long interest in understanding pathophysiological mechanisms of nausea and gastroparesis. Dr. Koch has studied extensively gastric myoelectrical activity (GMA) using serosal electrodes in animals and cutaneous electrodes in the study of normal 3 cpm GMA in humans. These studies have led to understanding gastric dysthymias are present in various nausea syndromes. In addition, a functional obstructive gastroparesis subtype was described that reflects pyloric dysfunction and response to endoscopic therapies with botulinum toxin A injection or balloon dilation. Dr. Koch is a PI in the NIH-sponsored Gastroparesis Clinical Research Consortium. Dr. Koch has written 143 peer-reviewed publications, 43 chapters, and 2 books.
 
Sponsored by the Association of Gastrointestinal Motility Disorders, Inc. AGMD
 

AGMD is privileged to present our AGMD Conversations with Dr. Kenneth Koch, MD series.
Every other month, we will be talking with Dr. Koch and focusing on various topics related to gastroparesis.
August is Gastroparesis Awareness Month, and Dr. Koch answers questions about gastroparesis submitted by our audience participants.
Kenneth L. Koch, MD, is a Professor of Medicine, Section on Gastroenterology & Hepatology, at Wake Forest Baptist Medical Center. He has a career-long interest in understanding pathophysiological mechanisms of nausea and gastroparesis. Dr. Koch has studied extensively gastric myoelectrical activity (GMA) using serosal electrodes in animals and cutaneous electrodes in the study of normal 3 cpm GMA in humans. These studies have led to understanding gastric dysthymias are present in various nausea syndromes. In addition, a functional obstructive gastroparesis subtype was described that reflects pyloric dysfunction and response to endoscopic therapies with botulinum toxin A injection or balloon dilation. Dr. Koch is a PI in the NIH-sponsored Gastroparesis Clinical Research Consortium. Dr. Koch has written 143 peer-reviewed publications, 43 chapters, and 2 books.
This program is sponsored by the Association of Gastrointestinal Motility Disorders, Inc. | AGMD |.